We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Syndax Pharmaceuticals Inc | NASDAQ:SNDX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.08 | 0.37% | 21.94 | 21.93 | 21.94 | 22.66 | 21.90 | 22.39 | 352,524 | 20:30:08 |
From May 2021 to May 2024
By Robb M. Stewart
Syndax Pharmaceuticals Inc. said the U.S. Food and Drug Administration has granted fast-track designation to its leukemia treatment SNDX-5613.
The biopharmaceutical company said Monday the designation underscores the potential of SNDX-5613 for the treatment of adult and pediatric patients with relapsed or refractory acute leukemias harboring a mixed lineage leukemia rearranged or nucleophosmin mutation.
FDA fast-track designation is designed to help development and expedite the review of drugs to treat serious conditions with an unmet medical need.
Syndax's shares were 5.4% higher in premarket trading, after ending Friday at $18.36, down 17% so far in 2021.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
June 28, 2021 08:12 ET (12:12 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Syndax Pharmaceuticals Chart |
1 Month Syndax Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
